Volume | 310,181 |
|
|||||
News | - | ||||||
Day High | 0.935 | Low High |
|||||
Day Low | 0.8511 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Vincerx Inc | VINC | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.9272 | 0.8511 | 0.935 | 0.8771 | 0.93 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
1,078 | 310,181 | US$ 0.8936821 | US$ 277,203 | - | 0.61 - 9.3722 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:55:57 | 25 | US$ 0.8764 | USD |
Vincerx Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
406.23M | 21.38M | - | 0 | -40.16M | -1.88 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Vincerx News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VINC Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.79 | 0.935 | 0.6607 | 0.7929557 | 664,760 | 0.0868 | 10.99% |
1 Month | 5.92 | 6.07 | 0.6607 | 1.29 | 1,681,836 | -5.04 | -85.19% |
3 Months | 1.35 | 9.3722 | 0.6607 | 3.06 | 1,271,115 | -0.4732 | -35.05% |
6 Months | 0.9503 | 9.3722 | 0.61 | 2.49 | 868,852 | -0.0735 | -7.73% |
1 Year | 1.57 | 9.3722 | 0.61 | 2.35 | 478,339 | -0.6932 | -44.15% |
3 Years | 15.91 | 18.4265 | 0.61 | 3.61 | 246,392 | -15.03 | -94.49% |
5 Years | 20.12 | 26.75 | 0.61 | 4.28 | 230,115 | -19.24 | -95.64% |
Vincerx Description
Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are primarily conducted in the United States. It focuses to develop, use, manufacture, commercialize, sublicense and distribute a clinical-stage and follow-on small molecule drug program and a preclinical stage bioconjugation/next-generation ADC platform. |